CORDIS
EU research results

CORDIS

English EN

European Network of Vaccine Development and Research

Project information

Grant agreement ID: 228403

Status

Closed project

  • Start date

    1 October 2009

  • End date

    30 September 2013

Funded under:

FP7-INFRASTRUCTURES

  • Overall budget:

    € 11 871 094,27

  • EU contribution

    € 9 899 999

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany

Objective

The TRANSVAC infrastructure will accelerate the pharmaceutical and clinical development of promising vaccine candidates by bringing the gap between academic research and clinical trials through carefully managing the advancement of promising vaccine candidates from preclinical animal models to early proof-of-principle studies in humans. Although expertise already exists within Europe spanning different disease types, there is currently very limited coordination between vaccine R&D groups, assay developers and vaccine producers. Unarguably, fragmentation of expertise and facilities has slowed, and in some instances distinctly impeded, the development and validation of promising vaccine candidates. To address these challenges the European vaccine development community needs to establish a collaborative vaccine development infrastructure based on shared visions and goals. The European Vaccine Initiative (EVI) and the Tuberculosis Vaccine Integrated (TBVI) Project have each demonstrated significant success in creating the know-how and infrastructures to enable the advancement of European vaccine development. In order to sustain the momentum generated by EVI and TBVI these successes will be built-upon to create an infrastructure driven by EVI, in which all stakeholders commit to sharing facilities and knowhow on vaccine development. This consortium (TRANSVAC) will comprise major European stakeholders with expertise, resources and facilities for each stage of vaccine development, from the scientific community as well as vaccine developers. Each stakeholder can add to what EVI and TBVI have already established by adding their own expertise to the TRANSVAC long term strategy. TRANSVAC will be the European driving force for vaccine development, and will be accessible to any interested parties. This consortium will initiate a new era in the innovative, harmonised and rapid development of accessible and efficacious vaccines for Europe and the rest of the world.

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV

Address

Vossstrasse 2 Geb 4040
69115 Heidelberg

Germany

Activity type

Research Organisations

EU Contribution

€ 2 116 215,72

Administrative Contact

Odile Leroy (Dr.)

Participants (14)

STICHTING BIOMEDICAL PRIMATE RESEARCH CENTER

Netherlands

EU Contribution

€ 1 404 380,36

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 577 460,33

VAKZINE PROJEKT MANAGEMENT GMBH

Germany

EU Contribution

€ 23 100

LIONEX GMBH

Germany

EU Contribution

€ 959 975

ID-LELYSTAD, INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID B.V.

Netherlands

EU Contribution

€ 86 615,36

Public Health England an Executive Agency of the Dept of Health

United Kingdom

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 979 494,97

UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 229 006,82

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

United Kingdom

EU Contribution

€ 339 000

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 900 495

UNIVERSITE DE LAUSANNE

Switzerland

EU Contribution

€ 656 775,56

STICHTING TUBERCULOSIS VACCINE INITIATIVE

Netherlands

EU Contribution

€ 85 107,28

STICHTING WAGENINGEN RESEARCH

Netherlands

EU Contribution

€ 586 018,06

Department of Health

United Kingdom

EU Contribution

€ 956 354,54

Project information

Grant agreement ID: 228403

Status

Closed project

  • Start date

    1 October 2009

  • End date

    30 September 2013

Funded under:

FP7-INFRASTRUCTURES

  • Overall budget:

    € 11 871 094,27

  • EU contribution

    € 9 899 999

Coordinated by:

EUROPEAN VACCINE INITIATIVE EWIV

Germany